Hepatitis Monthly

Published by: Kowsar

A Survey of Correlation Between Insulin-Like Growth Factor-I (IGF-I) Levels and Severity of Liver Cirrhosis

Asghar Khoshnood 1 , * , Mohsen Nasiri Toosi 2 , Mohammad Jafar Faravash 2 , Alireza Esteghamati 3 , Hosein Froutan 2 , Hadi Ghofrani 2 , Mohammad Kalani 2 , Arash Miroliaee 2 , Ahmad Abdollahi 4 and Andrabi Yasir 2
Authors Information
1 Department of Internal Medicine, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran
2 Department of Gastroenterology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Endocrinology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: February 01, 2013, 13 (2); e6181
  • Published Online: February 23, 2013
  • Article Type: Research Article
  • Received: May 9, 2012
  • Revised: June 13, 2012
  • Accepted: July 28, 2012
  • DOI: 10.5812/hepatmon.6181

To Cite: Khoshnood A, Nasiri Toosi M, Faravash M J, Esteghamati A, Froutan H, et al. A Survey of Correlation Between Insulin-Like Growth Factor-I (IGF-I) Levels and Severity of Liver Cirrhosis, Hepat Mon. 2013 ; 13(2):e6181. doi: 10.5812/hepatmon.6181.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997; 336(9): 633-40[DOI][PubMed]
  • 2. Friedrich N, Alte D, Volzke H, Spilcke-Liss E, Ludemann J, Lerch MM, et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res. 2008; 18(3): 228-37[DOI][PubMed]
  • 3. Life JS, Kipgen WW. Guidelines for the Diagnosis and Treatment of Adult Growth Hormone Deficiency 2011;
  • 4. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989; 10(1): 68-91[PubMed]
  • 5. Baxter RC. The somatomedins: insulin-like growth factors. Adv Clin Chem. 1986; 25: 49-115[PubMed]
  • 6. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16(1): 3-34[PubMed]
  • 7. Chen YH, Hung PF, Kao YH. IGF-I downregulates resistin gene expression and protein secretion. Am J Physiol Endocrinol Metab. 2005; 288(5)-27[DOI][PubMed]
  • 8. Thoren MC, Wivall-Helleryd IL, Blum WF, Hall KE. Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol. 1994; 131(1): 33-40[PubMed]
  • 9. Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol. 1997; 27(5): 796-802[PubMed]
  • 10. Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G. Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest. 1991; 14(4): 317-21[PubMed]
  • 11. Cuneo RC, Hickman PE, Wallace JD, Teh BT, Ward G, Veldhuis JD, et al. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol (Oxf). 1995; 43(3): 265-75[PubMed]
  • 12. Donaghy A, Ross R, Wicks C, Hughes SC, Holly J, Gimson A, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology. 1997; 113(5): 1617-22[PubMed]
  • 13. Scharf JG, Schmitz F, Frystyk J, Skjaerbaek C, Moesus H, Blum WF, et al. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol. 1996; 25(5): 689-99[PubMed]
  • 14. Shmueli E, Stewart M, Alberti KG, Record CO. Growth hormone, insulin-like growth factor-1 and insulin resistance in cirrhosis. Hepatology. 1994; 19(2): 322-8[PubMed]
  • 15. Chang TC, Lin JJ, Yu SC, Chang TJ. Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology. 1990; 11(1): 123-6[PubMed]
  • 16. Donaghy AJ, Delhanty PJ, Ho KK, Williams R, Baxter RC. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol. 2002; 36(6): 751-8[PubMed]
  • 17. Shen XY, Holt RI, Miell JP, Justice S, Portmann B, Postel-Vinay MC, et al. Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab. 1998; 83(7): 2532-8[PubMed]
  • 18. Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R. Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology. 1995; 21(3): 680-8[PubMed]
  • 19. Petersen KF, Jacob R, West AB, Sherwin RS, Shulman GI. Effects of insulin-like growth factor I on glucose metabolism in rats with liver cirrhosis. Am J Physiol. 1997; 273(6 Pt 1)-93[PubMed]
  • 20. Shmueli E, Miell JP, Stewart M, Alberti KG, Record CO. High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology. 1996; 24(1): 127-33[DOI][PubMed]
  • 21. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8): 646-9[PubMed]
  • 22. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3): 797-805[DOI][PubMed]
  • 23. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124(1): 91-6[DOI][PubMed]
  • 24. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterol. 2003; 50(51): 814-6[PubMed]
  • 25. Wu YL, Ye J, Zhang S, Zhong J, Xi RP. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol. 2004; 10(18): 2740-3[PubMed]
  • 26. Lou M, Song N, Jin X, Luo SQ, Wang JJ. [Detection of serum free insulin-like growth factor 1 in patients with chronic viral hepatitis]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001; 15(3): 291-2[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments